



# ANNUAL REPORT

## *2014/2015*





# For over thirty years the Children's Leukaemia & Cancer Research Foundation (Inc.) has been raising funds for research into childhood cancers.

The Foundation relies on the generous support of the community to continue its vital research, as we do not receive State or Federal funding.




## WHO ARE WE?

The creation of the Foundation was inspired by nine year old Jennifer Harper, who was diagnosed with leukaemia in 1977. When her father, Peter Harper, discovered that there was no research into children's leukaemia being done in Western Australia, he set out, together with other parents of children with cancer, to raise funds for this purpose. Sadly Jennifer passed away in 1978.

Australia has one of the highest incidences of childhood cancer worldwide. One in 500 Australian children will develop a cancer before 15 years of age – that's 600 Australian children diagnosed every year. Childhood cancer is the single greatest cause of death from disease in Australian children, with three children losing their lives to cancer every week. In Australia, childhood cancer is second only to breast cancer in terms of the number of years of life lost by the disease.

The quest to find cures for childhood cancer is one of medicine's greatest success stories. Fifty years ago only two percent of children with



cancer survived. Medical research alone has improved overall survival rates to 80 percent. With childhood cancer still the leading cause of death from disease in Australian children, there is more work to be done. There are still particular childhood cancers – such as brain tumours and neuroblastoma – with survival rates as low as 50 percent.

CLCRF has a commitment to ensure this ground-breaking research continues so that the future generations will be the ones to live cancer free. The Foundation relies on the generous support of the community to continue its vital research, as we do not receive State or Federal funding.

## TABLE OF CONTENTS

|    |                              |    |  |
|----|------------------------------|----|--|
| 04 | LIST OF OFFICE BEARERS       | 54 | FINANCIAL STATEMENTS                       |
| 05 | CHAIRMAN'S REPORT            | 55 | > STATEMENT BY THE COMMITTEE OF MANAGEMENT |
| 12 | EXECUTIVE OFFICER'S REPORT   | 57 | > OPERATING STATEMENT                      |
| 26 | CLCRF LAB REPORT             | 58 | > BALANCE SHEET                            |
| 43 | DONATIONS \$100 & ABOVE 2015 | 59 | > AUDIT REPORT FOR YEAR ENDED              |
| 48 | SCHEDULE OF MEMBERS          |    |  |



# Committee of Management

**Mr Geoffrey CATTACH, AM**  
(Chairman)

**Mr Philip BRUCE**  
(Vice Chairman)

**Mr Kim WILLIAMSON**  
(Treasurer)

**Mr David CATTACH**  
(Secretary)

**Mr Kimon ANDERSON**

**Mr Justin BRUCE**

**Professor Cathy COLE**  
(Nominee of Princess Margaret Hospital)

**Ms Natalie HIDDLESTONE**

**Professor Ursula KEES**  
(Nominee of Telethon Kids Institute)

**Mr Michael PARKER**

**Mrs Valerie STOPP**

**Mr John VIEIRA**

**FOUNDER**  
Mr Peter HARPER

**TRUSTEES**  
Mr Geoffrey CATTACH  
Professor Ursula KEES  
Mr Kim WILLIAMSON

**ADMINISTRATION STAFF**  
Mrs Andrea ALEXANDER  
(Executive Officer)  
Mrs Wendy KEARNS  
(Executive Assistant)  
Miss Katelyn LUSH  
(Administrative Assistant)

## Chairman's Report

It is with pleasure that I once again report to members on the operations of the Children's Leukaemia & Cancer Research Foundation (Inc) for the year ended 30th June 2015.



It has been a difficult year in many ways as our Foundation has had to meet the challenges of the trials and tribulations of a stifled economy after many years of financial viability, notwithstanding that we have been able to not only maintain but increase our research funding given an excellent accumulated fund position.

### Finance:

For the year under review the Foundation suffered its first loss from our operations, the deficit being \$807,269. There were a number of contributing factors relative to this result however I will allow the Treasurer to outline these in more specific detail in his report. What is a counter-balance to the deficit is that it follows outstanding profit outcomes of \$1,023,960 in 2014 and \$935,643 in 2013, both years which significantly exceeded budgeted expectations.

It is needless to say that our Board of Management has been pro-active to this year's result by putting in place a sub-committee to specifically investigate ways and means of introducing new income streams as well as improving existing ones – more on this later.

### Funding of Grants:

Due to the build-up of our accumulated funds over the past 30 years, the Foundation has been able to increase its overall funding of grants and in the year under review expended a total of \$1.1m. A snapshot of the grants currently being funded is as follows:

- (i) **Triennial Block Grant 2015 - 2018**  
Titled Testing New Drugs for Infants with High Risk Leukaemia amounting to \$1,396,313
- (ii) **\$1M Recognition of Excellence Funding Grant 2013 - 2017**  
Titled Molecular Genetics of Childhood Tumours amounting to \$1,000,000
- (iii) **CLCRF Fellowship Grant 2014 - 2016**  
Titled Targeting Therapy and Disease Outcomes in Paediatric Cancers amounting to \$557,167
- (iv) **Woolworths WA Research Fellowship 2013 - 2015**  
Titled Identifying the Molecular Abnormalities in Childhood Leukaemia amounting to \$400,000
- (v) **Midline Carcinoma Grant 2015 - 2017**  
Titled Effective Therapies for NUT Midline Carcinoma amounting to \$110,702
- (vi) **Morpholino Therapy for Cancer Grant 2015 - 2017**  
Titled The Molecular Genetic Landscape for Morpholino Therapies amounting to \$21,180
- (vii) **Co-funding Professor of Paediatric Research Grant 2015/2017** amounting to \$600,000





Again our congratulations and heartfelt appreciation is extended to Professor Ursula Kees and her dedicated team of researchers for their continued achievements both locally and internationally.

#### Telethon Kids Institute:

I am pleased to once again acknowledge our wonderful relationship we enjoy with the Telethon Kids Institute who administer and provide the necessary infrastructure for the Children's Leukaemia & Cancer Research Laboratory which we fund.

We extend our appreciation to both Professor Jonathan Carapetis, the Institute's Director, along with Tim McInnis, Head of Development, for continuing to enhance our partnership which gives true meaning to what the Institute espouses, and that is to 'Discover', 'Prevent', 'Cure'.

#### Professor In Paediatric Research:

The Foundation is pleased to have been invited by the Telethon Kids Institute to co fund, with the Cancer Research Trust, the establishment of a position of Professor / Senior Researcher in Paediatric Cancer Research to undertake the highest quality research into childhood cancers.

Last year we reported to you that we had agreed 'in principle' subject to finalising a funding agreement, to support the proposal. I am now pleased to advise that we have finalised the agreement and are delighted that this arrangement will prove, in the fullness of time, to strongly reinforce our relationship with the Institute, enhance childhood cancer research and assist in the future stewardship of the CLCRF Research Laboratory.

#### Marketing Strategy & Development:

The appointment of Kylie Dalton of Absolute Edge Media in 2013, to create, manage and coordinate all of the Foundation's marketing, branding, promotion as well as identify and develop new community and media relationships, now enters its third year.

Over the past 12 months Kylie has proven to be outstanding in her endeavours and has been re-appointed until 30th June 2016. Our Executive Officer will report specifically on what has been undertaken for the year under review.

#### Community Activities:

Once again we are amazed at the wonderful and diverse support we receive from benefactors, businesses and the community at large.

Whilst such contributions will be individually acknowledged in our Executive Officer's Report, I would pay particular mention of the wonderful contribution of the South West Bike Trek which this year raised the magnificent sum of \$47,280 and since its inception in 2004 has raised a total of approx \$609,000.

In February 2015 we announced our Young Ambassadors, Chloe Clements and Caitlin Garrett. Both of these young ladies are motivated and passionate about helping the Foundation raise awareness and source funding for childhood cancer research.

The inaugural Benefit Concert, titled 'Rhythms of Life' was held at the Regal Theatre in April 2014. This event featured seasoned WA performers Caroline McKenzie, Trudy Dunn, Sharon Kiel and Sue Bluck and gave attendees a wonderful theatrical morning of music and entertainment.

Also the hash tag campaign "Our Motive to Move" – (overarching marketing strategy being created with a view for implementation in the 2016 year) work has been started.

To the many others who have supported our Foundation in varied and innovative ways throughout the past year please accept our grateful appreciation.







### **Governance Issues:**

Over the past two years the Foundation has undertaken to address governance issues in particular with regulations with the new ACNC Act (Australian Charities & Not for Profit Commission) and the drafting of a new Constitution which requires updating after 30 years and compliance with the ACNC Act.

It is pertinent to note that the purpose of the ACNC is to set out a minimum standard of governance and to promote public trust and confidence in registered charities.

We are particularly indebted to Allion Lawyers who have gratuitously undertaken to oversee the drafting of a new constitution and to ensure compliance with all statutory authorities. We are also indebted to R Scales & Company who have provided necessary advice – legal and otherwise - regarding compliance with Public Ancillary Fund Guidelines.

The drafts are now finalised and an extraordinary general meeting of members will be called next February to adopt the new constitution.

### **Strategic Review:**

Given the deficit experienced from our operations during 2014/15, the Board of Management appointed a sub-committee - under the chairmanship of Kimon Anderson – whose aim primarily was to investigate new income streams and look to improve existing ones.

After their initial meeting, the sub-committee reported back to the Board suggesting that they felt in order to compete satisfactorily for the 'available corporate dollar' they needed to be sure that we had an updated and relevant CLCRF profile. Accordingly the Board supported their need for a complete strategic review to be undertaken.

Accordingly Ak Sabbagh of AltusQ and Kirsten Pilatti have been appointed to assist with the independence of a strategic review. We are confident that the outcomes of this review will be instrumental with ensuring our Foundation is not only 'up with the pack' but to the forefront in the future.



**Patron:**

Justin Langer has proved on many fronts that he is a person of great integrity and has been an outstanding achiever in whatever he undertakes whether it is on the cricket field or as a proud and passionate family man.

We were extremely fortunate to have Justin accept the position of our first Patron and it is no surprise that he still holds this position. Notwithstanding his many commitments he has always given his support to the Foundation whenever called upon.

I am pleased to announce that Justin has agreed to continue in this role for the next 12 months.

**Ambassador:**

During the past year we were most fortunate to have agreement from the Right Honourable Lord Mayor Lisa M Scaffidi – to accept the position of Foundation Ambassador.

Ms Scaffidi has shown significant interest in the objectives and operations of our Foundation and has been an outstanding supporter in a number of our activities, particularly our “Dance for a Cure”.

As Ambassador, Ms Scaffidi, is well placed to assist in bringing an awareness of the Foundation to the community at large and we are most grateful for her support.

**Foundation Staff:**

The Foundation is most fortunate to have competent and enthusiastic staff looking after our administrative needs.

To Andrea Alexander, Wendy Kearns and Katelyn Lush, I extend my personal appreciation for your loyalty and dedication as well as being wonderful ambassadors of the Foundation.

**Board of Management:**

We are also fortunate to have very dedicated and enterprising members of our Board of Management, all of whom give willingly of both their time and expertise ensuring that our Foundation operates efficiently and effectively.

I am personally extremely grateful to each and every member of the Board of Management, all who certainly make my role as Chairman a pleasure.



## CONCLUSION

One of the more pleasing aspects of my role as Chairman is to witness at first hand the amazing growth of our membership and the diversity and enterprise of all who contribute to the aims and objectives we espouse. To these wonderful persons, who represent the adage of ‘people helping people’ we extend our sincere appreciation and welcome you to the Foundation’s ‘family’.

To all the other wonderful community groups and individuals who support our funding strategies we are eternally grateful.

I wish everyone a very Merry Xmas and look forward to an exciting New Year.

A handwritten signature in black ink, reading 'Geoffrey R Cattach'.

**Geoffrey R Cattach AM**  
**CHAIRMAN**

**November 2015**





# Executive Officer's Report

I am pleased to report to the Members of the Children's Leukaemia & Cancer Research Foundation (Inc) on operational matters for the financial year 2014/2015.

## Corporate Benefactors



### PwC – 2014 Cool Night Classic

The Foundation was chosen as the beneficiary of the 2014 PwC Cool Night Classic, held in November. A donation of \$35,000 was received from this unique event.

### Wellard Group

The Wellard Group continued to support the Foundation via the annual Xmas function and the Wellard 'Star of the West' Campdraft. Generous donation/s totalling \$21,212 were received.



## Benefactors

### Deceased Estates

|   |           |
|---|-----------|
| Lee John Henry - WA (final distribution)    | \$ 87     |
| Kakulas Michael – WA                        | \$ 2,000  |
| Ferguson Phyllis – WA                       | \$ 10,000 |
| Reilly Brian – WA                           | \$ 1,000  |
| Jenkins Marjorie – NSW (final distribution) | \$ 2,940  |
| Guest Ethel – NSW                           | \$ 100    |

The Foundation was not aware of some of these gifts until the benefactors had passed away.



**2014 Teen Ball & Glass Slipper Ball - \$26,137**

These two events were organised by Kasey Carr, with help from Caitlin Garret, Chloe Clements and Océane Bourgault (all cancer survivors).

The Teen Ball, held in August, was to give ‘cancer teens’ something to look forward to and take their minds off their treatment and the endless visits to the hospital. The Glass Slipper Ball was held in October. Funds were raised from ticket sales and an auction on the night of the adult ball.



**Mr John Hughan  
\$11,000**

Mr Hughan has been supporting CLCRF for many years.



**Stan Perron  
Charitable  
Foundation -  
\$10,000**

Mr Perron and his Foundation have been very charitable supporters of the Foundation since 1996.



**Lodge Golden Bea-  
con No 14 WAC \$  
10,000**

This donation is a first from this organisation and its members.

**Tate Family Foundation -  
\$25,000**

This donation represents the fourth year of the Tate Family's commitment towards the \$1M Recognition of Excellence grant.

*To these individuals and organisations we extend our sincere thanks for their support of the Foundation. There were many others who have provided support and financial assistance during 2014/2015. Their generosity is greatly appreciated. Donations of \$100 and above are listed elsewhere in this report.*





## 2015 Family Night Out – Keep the Flame Alive Event



Our sixth family concert was held at Houghton Winery in March. Attendees were entertained by Gary Anderson and his Ultimate Rock N Roll show and children's entertainer, Zalia Joi.

The concert would not have been possible without support from Houghton Winery, BBC Entertainment, Royal Life Saving Society (WA) and Australian Protection Services. Appreciation also to Twisted Balloons, Matt Brenner and family and our CLCRF volunteers.

The object of the family night out is to afford our members and supporters a event for a reasonable cost and to lift our profile within the community.

## 2015 Rhythms of Life Benefit Concert – Keep the Flame Alive Event

The inaugural Benefit Concert was held at the Regal Theatre in Subiaco in April. This event featured seasoned WA performers Caroline McKenzie, Trudy Dunn, Sharon Kiely and Sue Bluck, who treated the audience to a theatrical morning of music and entertainment.





## Tele-Marketing Raffles

There were three raffles completed during the year ending June 2015. Revenue from these raffles totalled \$409,705 which, after expenditure resulted in a surplus of \$134,405. Donations received via the raffles were included in the revenue figure.

Although the surplus figure was down compared with last year, it must be noted that there are many other charities now utilising this type of fundraising. Our raffles continue to increase our profile in the community around Australia.

The Royal Life Saving Society WA (RLSSWA), through its call centres in Manjimup and Bridgetown, continue to undertake our telemarketing calls and the Hello Call Centre look after the administration of the raffle funds. These raffles are on a cost recovery basis and RLSSWA make no profit from the Foundation's raffles.

## Donation Appeal Campaigns

From each raffle campaign the Foundation has been able to establish a database of donors in addition to raffle supporters. Tax and Xmas donation appeals were sent to this donor database in 2014/15, as well as to a select number of donors from the Foundation database.

All four campaigns were successful and represent an effective complimentary fundraising program to the raffles. Net cash received from the campaigns was \$107,729, which is higher than last year.



## 2014 South West Bike Trek

The Foundation's 12th South West Bike Trek kicked off in Mandurah on Monday the 13th October and finished in Augusta on Saturday the 18th. This year 30 cyclists took part in the 600 kilometre ride.

This event would not be possible without the support of the many service clubs, shires, companies and individuals. A total of \$47,280 was raised from the trek.





## 2015 ANZCHOG Conference

### ANZCHOG

Australian and New Zealand  
Children's Haematology/Oncology Group

#### ANNUAL SCIENTIFIC MEETING

**DIFFICULT DISEASES  
DIFFICULT SITUATIONS**

**18 - 20 JUNE 2015**

Esplanade Hotel Fremantle -  
by Rydges, Fremantle WA



The Australian and NZ Children's Haematology/Oncology Group (ANZCHOG) conference was held in Perth during June.

The theme was 'Difficult Diseases, Difficult Situations' and promised to deliver an exciting program which explores the increasing challenges involved with the provision of high quality paediatric haematology and oncology care whilst being able to meet the expectations of patients and families.

Valuable and insightful discussions around the theme were presented by a number of invited international and local speakers recognised for being leaders in their fields.

The CLCRF had the pleasure of sponsoring Professor Richard Lock, from the Children's Cancer Institute in NSW. Professor Lock collaborates with Professor Ursula Kees and her team, on research into acute lymphoblastic leukaemia.



## FIA Awards

The Foundation received two awards from the Fundraising Institute of Australia (FIA) in the 2014 State Awards of Excellence. We were Winners for the category Special Events - Under \$5 Million for our 'Longest Awareness Ribbon' and received a Highly Commended Award for the category 'Donor Renewal - Under \$5M' for our 'All They Needed Was A Nudge' campaign.





## Foundation Update

Three editions of the Foundation Update were published during the period under review. The look of the Update has been refreshed, thanks to Michele Seymour from Absolute Edge Media and her expertise in this area.



## Website

[www.childcancerresearch.com.au](http://www.childcancerresearch.com.au)

Our website continues to be visited by people from around the world and is a very useful tool in building our profile in the community at large. We would like to acknowledge Phil Solomon, of Topshelf, who maintains our web site at no cost to the Foundation.

The CLCRF website is currently undergoing a complete revamp (via a grant received from Lotterywest to assist with this cost). The new website will be launched very soon. This site will merge the CLCRF and the Keep the Flame Alive site.



## Social Media

[www.facebook.com/CLCRF](http://www.facebook.com/CLCRF)

Currently CLCRF has 2,802 Facebook followers and provides a useful communication platform for engaged members/supporters. Positive feedback has been received as to our facebook content – getting the right mix of information, interesting items and humour is paramount to attracting 'LIKES'.

[www.facebook.com/flamealive](http://www.facebook.com/flamealive)

The KTF facebook page also has 2,544 likes. This page is used mainly to promote our events.

[twitter.com/CLCRF](https://twitter.com/CLCRF)

We currently have 114 followers on Twitter. The Twitter account is mainly used when at events eg Dance For A Cure, Swan River Run, PwC Cool Night Classic.

These social media platforms have proved to be of great benefit to the Foundation.



## Membership

As at November the Foundation has 636 members. New members have signed up during the past year, whilst some of our existing members have passed away.



## Fund Raising Platforms

Support for the Foundation has continued to come from many people around the world. CLCRF's fundraising profile continues to be strong via the online fundraising entities such as Everyday Hero, Go Fundraise and My Cause.

Funds raised via these platforms totalled \$27,561 during 2014/15. These fundraising platforms are an excellent way for people to support the cause.



## School/College Support

The Foundation again saw continued support from schools and colleges around Australia. It is heart-warming to acknowledge 'children helping children'. Particular mention must be made of Christ Church Grammar – Romsey House, who have supported the Foundation since the late 1980's.



## CONCLUSION

This year has been one of the most challenging we have ever experienced and it is the first time in 19 years that the Foundation has not had surplus funds at the end of a financial period. Our cause is not the only one feeling this down turn, charities around Australia are all doing it tough. Forecasts for 2016 do not look any better – so CLCRF will endeavour to look at various other ways of raising funds for childhood cancer research.

In March 2015 Wendy and I attended the Fundraising Institute of Australia's international conference in Brisbane. For not-for-profit organisations, attendance at these conferences is essential to stay in touch with the industry and to network with peers. Thank you to the Committee for their support of this professional development.

Thank you to my Executive Assistant, Wendy Kearns and our Administrative Assistant, Katelyn Lush for their endless support during the past year.

Our Board of Management continue to provide me with support and guidance. It is an honour to work for such a dedicated group of people.

I would like to take this opportunity to wish everyone a very Merry Christmas and a safe and peaceful 2015.

**Andrea Alexander**  
EXECUTIVE OFFICER

**November 2015**





# CHILDREN'S LEUKAEMIA & CANCER RESEARCH 2014/2015

**Funding:** Triennial Block Grant (2012 – 2015 and 2015 - 2018)  
**Researcher:** Professor Ursula R Kees  
**Title:** Testing New Drugs for Infants with High-risk Leukaemia



Newborns and very young children diagnosed with leukaemia face a dismal outlook, in sharp contrast to children who are older than 12 months at the time of diagnosis. Some of the older patients achieve a 5-year survival of 95%. Strikingly, in leukaemia patients less than 3 months at the time of diagnosis, the survival rate is only 30%.

In an attempt to find better therapy for these patients, international study groups have conducted many studies, and the babies were given more intensive therapy. Unfortunately, this led to a large number of toxic deaths, and did not improve overall survival. We urgently require novel therapy for these patients, and understanding the biology of this disease holds the key. To study the biology we investigated the genetic

features of the leukaemia cells from babies, and performed genetic analyses using state-of-the-art next generation sequencing technology. We gained novel insight into which genes are involved, their contribution to disease progression and resistance to chemotherapeutic drugs.

We confirmed that a gene called MLL is not in its normal position on chromosome number 11 where it normally is located, but the chromosome is broken at the site and fused to part of another chromosome. We know that such fusions that are only present in the leukaemia cells, not in the patient's normal cells, confer poor prognosis for the patient.

We also found that infant patients inherited extremely rare versions in other genes that are known to play a role in cancer. Importantly, these

molecular studies identified several known cancer-causing genes. This knowledge allows us to select modern drugs that target these altered genes to improve treatments of patients with infant leukaemia.

We used the leukaemia specimens from the patients to generate cell lines, such that the cells can be kept alive in the laboratory. These cell lines allow us to determine which drugs are effectively killing the leukaemia cells. We have generated a panel of nine cell lines and used the same methods to analyse their genetic features, as was done for the leukaemia cells from the patients.

This confirmed that the cell lines showed the identical fusions of the MLL gene as the ones found in the leukaemia cells from the patients. We then screened the panel of cell lines against 150 approved



cancer drugs, which is the first comprehensive assessment of the drug response in leukaemia cells from babies. The information obtained clearly showed that some of the currently used drugs are not very effective at killing the leukaemia cells in the test-tube.

However some of the novel drugs, eg Romidepsin and Bortezomib were very effective, yet are not used in contemporary protocols for patients. Importantly, we could show that some of these drugs enhance the effectiveness

of drugs that are currently used in the treatment of leukaemia patients. Taken together, these studies have identified drugs that could be useful to treat babies with leukaemia, including established anti-cancer drugs as well as new-generation drugs. For the first time we have shown that a combination of a novel drug and a currently used drug is more powerful than each one alone. Currently we are optimizing administration of the two drugs together; they are expected to provide great benefits in the treatment of

patients with this disease. Our results have been presented to members of the international study group Children's Oncology Group, and they intend to include our findings in the plans for future clinical trials on infants with leukaemia.

These and other studies have generated a number of research publications and have allowed us to leverage additional funding to support the work. These details are provided below:

#### Additional Funding Leveraged:

- Telethon - Perth Children's Hospital Research Fund (2015-2017): Combinatorial therapeutics in high-risk infant acute lymphoblastic leukaemia (Kotecha RS, Kees UR, Cruickshank, MN, Lassmann T, \$237,180)
- The Kid's Cancer Project Grant (2015): Improving the treatment for infants with leukaemia (Kees UR, Cruickshank M, \$115,000).
- The Kid's Cancer Project Grant (2014): Improving the treatment for infants with leukaemia (Kees UR, Cruickshank, M, \$100,000).
- NHMRC Project Grant ID1011499 (2011-2015): Targeting drug-resistance in childhood leukaemia (Kees UR, Lock RB, Beesley AH, \$626,732).
- NHMRC Project Grant ID1007586 (2011-2014): The role of connective tissue growth factor in the pathobiology of lymphoid tumours and response to therapy (Kees, UR, Beesley AH, Charles AK, \$601,732).

#### Recent Publications:

Cruickshank MN, Ford J, Anderson D, Kotecha R, Cole C, **Kees UR**, 2015: Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of Romidepsin. Cancer Discovery, submitted.

Richmond J, Carol H, Evans K, High L, Mendo A, Robbins A, Meyer C, Venn NC, Marschalek R, Henderson M, Sutton R, Kurmasheva RT, **Kees UR**, Houghton PJ, Smith MA and Lock AB, 2015. Effective targeting of the P53/MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clinical Cancer Research, 2015, 21(6): 1395-1405.

Wells JE, Howlett M, Halse HM, Heng J, Ford J, Cheung L, Samuels AL, Crook M, Charles AK, Cole CH and **Kees UR**, 2015. High expression of connective tissue growth factor (CTGF) accelerates dissemination of leukaemia. Oncogene (under review).

Kotecha RS, **Kees UR**, Cole CH and Gottardo NG, 2015. Rare childhood cancers - an increasing entity requiring the need for global consensus and collaboration. Cancer Medicine, 2015, 4(6): 819-824.

Longville BA, Anderson D, Welch MD, **Kees UR**, Greene WK, 2015. Aberrant expression of aldehyde dehydrogenase 1A (ALDH1A) subfamily genes in acute lymphoblastic leukaemia is a common feature of T-lineage tumours. British Journal of Haematology 2015 Jan;168(2):246-57.

Stirnweiss A, McCarthy K, Oommen J, Crook ML, Hardy K, **Kees UR**, Wilton SD, Anazodo A, Beesley AH, 2015. A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma. Oncogenesis 2015 Nov 9;4:e174. doi: 10.1038/oncsis.2015.33

Welch MD, Howlett M, Halse HM, Greene WK, **Kees UR**, 2015. Novel CT domain-encoding splice forms of CTGF/CCN2 are expressed in B-lineage acute lymphoblastic leukaemia. Leukemia Research 2015, 39 (8): 913-920.

Kotecha RS, Gottardo NG, **Kees UR** and Cole CH, 2014. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer Journal (2014). 4.10.1038/bjc.2014.17.

Wells JE, Cole CH and **Kees UR**, 2014. Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. International Journal of Cancer, 2014 May. doi : 10.1002/ijc.28972.

Cheung CT, Strickland DH, Howlett M, Ford F, Charles AK, Lyons KM, Brigstock DR, Goldschmeding R, Cole CH, Alexander WS and **Kees UR**, 2013. Connective tissue growth factor is expressed in bone marrow stromal cells and regulates IL-7 dependent B lymphopoiesis. Haematologica, 2014.99(7):1149-1156.

Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, **Kees UR** and Lock RB, 2014. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. Blood Cancer Journal, 2014 Aug 1;4:e232. doi:10.1038/bjc.2014.52.

De Kock N, Sabbaghian, H, Druker E, Weber N, Hamel S, Miller CS, Choong S, Gottardo NG, **Kees UR**, Rednam SP, Van Hest L, Jongmans MC, Zacharin M, Bouron-Dal Soglio D, Malkin D, Priest JR, Perry A, Albrecht S, Grundy RG and Foulkes WD, 2014. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol. 2014 Oct; 128(4):583-95. doi: 10.1007/s00401-014-1318-7.

Hooper CM, Hawes SM, **Kees UR**, Gottardo NG and Dallas PB, 2014. Gene expression analyses of the spatio-temporal relationships of human medulloblastoma subgroups during early human neurogenesis. PLoS ONE 9(11): e112909. doi:10.1371/journal.pone.0112909

Samuels AL, Heng JA, Beesley AH and **Kees UR**, 2013. Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 2014. 165:57-66.

Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW, Arndt G, Charles AK, Cole CH and **Kees UR**, 2013. Comparative drug screening in NUT midline carcinoma. British Journal of Cancer, 2014.110(5):1189-98.

Welch MD, Greene WG and **Kees UR**, 2013. Hypomethylation of the CTGF gene locus is a common feature of paediatric pre-B acute lymphoblastic leukaemia. British Journal of Haematology, 2013, 162(4):537-41

Beesley AH, Firth MJ, Anderson D, Samuels AL, Ford J and **Kees UR**, 2013. Drug-gene modelling in pediatric T-cell acute lymphoblastic leukemia highlights importance of 6-mercaptopurine for outcome. Cancer Research, 2013, 73(9):2749-59.

Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, **Kees UR** and Beesley AH. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. Oncogene, 2013;32(39):4664-74.

Tesfai Y, Ford J, Carter KW, Firth MJ, O'Leary RA, Gottardo NG, Cole CH and **Kees UR**. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. Leukemia Research 2012, 36: 299.

Kotecha RS, Ford J, Beesley AH, Anderson D, Cole CH and **Kees UR**, 2012. Molecular characterization of identical, novel MLL-EP515 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia. Haematologica 2012 ;97(9):1447-50.

Francis RW, Thompson-Wicking K, Carter KW, Anderson D, **Kees UR** and Beesley AH, 2012. FusionFinder: a software tool to identify expressed gene fusion candidates from RNA-Seq data. PLoS One 2012;7(6):e39987.



**Funding:** Million Dollar Recognition Award (2012 – 2017)

**Researcher:** Professor Ursula R Kees

**Title:** Molecular Genetics of Childhood Tumours



Most children and young adults with leukaemia are diagnosed with acute lymphoblastic leukaemia or ALL. More than 50 years ago a few clinicians pioneered the use of what we call chemotherapy - drugs that are toxic and preferentially attack leukaemia cells.

A tremendous international cooperation by clinicians and scientist started to find combinations of drugs that can eliminate the ALL cells and cure the patients. Steady progress has pushed the cure rate in some childhood patients to 95%, yet close to 40% of deaths occur among patients who are expected to respond favourably to multi-drug therapy.

The burden of disease for childhood cancer is 67 person years life lost compared to

16 for breast cancer. Sadly, in some patients the disease comes back and the patients relapse. Most relapses of ALL occur in the bone marrow from where the disease originates.

At the time a patient is diagnosed, the bone marrow does not contain many normal cells, but instead contains about 95% ALL cells. The cause of relapse is often due to the fact that the chemotherapeutic drugs are not toxic to the leukaemia cells - because they have changed their genetic features somewhat and as a result have become resistant.

We have recently discovered that leukaemia cells use another escape method, and this is triggered by a response in the normal cells that surround them. This

seems to be a slow process and takes place in the bone marrow. It ultimately leads to protection of leukaemia cells by the microenvironment.

Our studies began when we made the discovery that a growth factor, which regulates interactions between cells, is highly expressed in ALL cells. It is called connective tissue growth factor, or CTGF for short. We found out that the ALL cells rapidly secrete CTGF such that cells in the vicinity receive a CTGF signal.

In order to find out what this signal might achieve, we generated ALL cells that secrete more or less of this growth factor. Our studies showed that CTGF promotes the growth of leukaemia, and that the cells surrounding the ALL cells respond to the

signal by growing faster. These neighboring cells in turn secrete other factors and signal to surrounding cells. These combined reactions of the surrounding cells appear to trigger expansion of the leukaemia cells. Our understanding of the cascade of events opens up new avenues to interfere with the process. The goal is to find inhibitors of this mechanism to stop the leukaemia from coming back.

#### Recent Publications:

Wells JE, Howlett M, Halse HM, Heng J, Ford J, Cheung L, Samuels AL, Crook M, Charles AK, Cole CH and **Kees UR**, 2015. High expression of connective tissue growth factor (CTGF) accelerates dissemination of leukaemia. *Oncogene* (under review).

Welch MD, Howlett M, Halse HM, Greene WK, **Kees UR**, 2015. Novel CT domain-encoding splice forms of CTGF/CCN2 are expressed in B-lineage acute lymphoblastic leukaemia. *Leukemia Research* 2015, 39 (8): 913-920.

Wells JE, Howlett M, Cheung CT and **Kees UR**. The role of CCN family genes in haematological malignancies, *J Cell Commun Signal* 2015, 9(3):267-78.

Cheung CT, Wells JE, Howlett M, Cole CH, and **Kees UR**. The bone marrow microenvironment for B-cell development, 2015. To be submitted December 2015.

Wells JE, Cole CH and **Kees UR**, 2014. Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. *International Journal of Cancer* 2014 May. doi : 10.1002/ijc.28972.

Stirnweiss A, McCarthy K, Oommen J, Crook ML, Hardy K, **Kees UR**, Wilton SD, Anazodo A, Beesley AH, 2015. A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma. *Oncogenesis* 2015 Nov 9;4:e174. doi: 10.1038/oncsis.2015.33

Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW, Arndt G, Charles AK, Cole CH and **Kees UR**. Comparative drug screening in NUT-midline carcinoma. *British J Cancer* 2014;110(5):1189-98.

Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, **Kees UR**, Beesley AH. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. *Oncogene* 2013;32(39):4664-74.

Francis RW, Thompson-Wicking K, Carter KW, Anderson D, **Kees UR**, Beesley AH, 2012. FusionFinder: A tool to identify expressed gene fusion candidates from RNA-Seq data. *PLoS One* 7(6):e39987

Tesfai Y, Ford J, Carter KW, Firth MJ, O'Leary RA, Gottardo NG, Cole CH and **Kees UR**. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. *Leukemia Research* 2012, 36: 299.



**Funding:** CLCRF Research Fellowship (2010 – 2013; 2013 – 2016)  
**Researcher:** Associate Professor Alex H Beesley  
**Title:** Targeting Therapy and Disease Outcomes in Paediatric Cancer



Dr Beesley has been employed within the CLCRF Laboratory in the Division of Cancer and Leukaemia Research since 2003, and was awarded the inaugural CLCRF Research Fellowship in July 2010.

This three-year Fellowship provided support for Dr Beesley to conduct research to investigate the ways in which patients with leukaemia become resistant to certain therapies, in particular steroids such as dexamethasone.

Our studies using bone marrow cells from leukaemia patients (grown in the test tube to generate cell lines) have helped us to identify some of the mechanisms associated with the development of drug resistance.

This includes specific changes to the metabolism of the cancer cells, which alters the way in which they use nutrients, for example sugar.

A second part of this study was the development of 'biomarkers' that can help in the early identification of leukaemia patients that are at risk of relapse. The accurate identification of patients at risk of relapse can improve treatment protocols for patients, tailoring the amount of therapy they receive to their level of risk. This improves not only cure rates, but also minimises secondary side effects of chemotherapy.

In 2013, Dr Beesley was successful in renewing his Fellowship, with the aim of conducting research into a

rare type of cancer called NUT midline carcinoma (or NMC). This is a terribly aggressive cancer that can affect children of all ages, and there is currently no cure.

Patients are treated with aggressive chemotherapy and surgery but survival is typically less than one year. The first report of this rare disease was published by Professor Kees in 1991, and we continue to be one of very few laboratories in the world studying its biology.

Thanks to the funding provided from the CLCRF, we have been able to obtain material from investigators and tumour banks around the world to generate a unique panel of NMC cell lines here in Perth. Using this comprehensive panel, we have started testing

for drugs that might be more effective at killing the cancer cells, and we have also sent the samples to have their entire genetic code analysed, the first time that this has been done for this disease. This information will provide a blueprint of what goes wrong in NMC cells and the types of drugs that might be best for treatment. In 2014 & 2015 he was awarded CLCRF Project Grants to further support this NMC research, and details of these projects are provided below.

Central to the success of these projects is the science of computational biology or 'bioinformatics', which is the use of high-performance computing to analyse the enormously complex

data that is generated by modern biological research approaches.

Since 2015 Dr Beesley has been actively developing the necessary bioinformatic skillsets to be able to analyse the data generated from the NMC research program and related projects. Building specialised capacity in cancer bioinformatics is critical for the future success of the Telethon Kids Cancer Centre and it is envisaged that Dr Beesley will play a key role in this space in 2016 and beyond.

As part of his Fellowship Dr Beesley has co-written two successful NHMRC Project Grant applications together with Professor Kees and has applied to the NHMRC

for additional funding to support the NMC research program. In 2014 he played a significant role in assisting Dr Anja Stirnweiss with her successful Raine Priming Grant submission, which provided additional funding for the NMC project.

He has published 12 journal articles during his Fellowship and has been responsible for presenting research from the laboratory to community groups and scientific audiences, both in Australia and overseas, acknowledging the support from the CLCRF at each opportunity.

#### Findings from research conducted during Dr Beesley's Fellowship have been presented in the following scientific forums and community groups:

- EMBL | Stanford Conference in Personalised Health, Heidelberg, Germany (2015).
- Paediatric Pathology Society and Australia and New Zealand Paediatric Pathology Group Joint Scientific Meeting, Perth, WA (2015)
- Australia & New Zealand Children's Oncology Group (ANZCHOG) Conference, Perth WA (2015)
- Combined Biological Sciences Meeting, Perth, WA (2015).
- The Lorne Genome Conference, Victoria (2015).
- The Australian Society for Medical Research (ASMR) Annual Symposium (2014-2015).
- Telethon Kids Institute Cancer Forum Seminar Series (2015)
- The iVEC Supercomputing Annual Symposium, Perth, Western Australia (2014).
- EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain (2014).
- The European Association for Cancer Research Conference, Cambridge, UK (2013)
- The 'Beyond the Genome' Conference, San Francisco, USA (2013).
- The American Society for Human Genetics, Boston, USA (2013).
- The Australian Society for Biochemistry and Molecular Biology (ASBMB) Annual Symposium, Fremantle, WA (2012, 2014).
- 4th New Directions in Leukaemia Research Conference, QLD (2012).
- New Directions in Child and Adolescent Health Symposium, Princess Margaret Hospital (2012).
- Children's Cancer Institute Australia (CCIA), Sydney (2012).
- The Lorne Cancer Conference, Victoria (2012, 2013).
- 28th Annual Genes & Cancer Meeting, Warwick, UK (2011).
- Keystone Symposium 'Omics Meets Cell Biology', Alpbach, Austria (2011).
- The Perth Cancer Club, WAIMR (2011).
- The Cancer Council WA Symposium, Perth, WA (2011 & 2013).
- The Lowy Symposium: Discovering Cancer Therapeutics, Sydney (2013).
- Rotary-Lions Club South West Bike Trek Fundraiser Dinner, Pinjarra (2012, 2013, 2014).

Together these studies have generated a number of important research publications and have allowed us to leverage additional funding to support the work:



Additional Funding Leveraged:

- Raine Priming Grant (2015-2016): Protein signaling networks in NUT Midline Carcinoma (Cl: Stirnweiss; Als Beesley AH, Kees UR, \$180,000).
- CLCRF Project Grant (2015): ‘Effective Therapies for Midline Carcinoma’ (Beesley AH, \$110,661 over 1 year).
- CLCRF Project Grant (2015): ‘Morpholino Therapy for Childhood Cancer’ (Beesley AH, \$21,180 over 1 year).
- NHMRC Project Grant ID1011499 (2011-2015): Targeting drug-resistance in childhood leukaemia (Kees UR, Lock RB, Beesley AH, \$626,732).
- NHMRC Project Grant ID1007586 (2011-2014): The role of connective tissue growth factor in the pathobiology of lymphoid tumours and response to therapy (Kees, UR, Beesley AH, Charles AK, \$601,732).
- CLCRF Research Fellowship (2013 - 2016): ‘Targeting therapy and disease outcomes in NUT Midline Carcinoma’ (Beesley AH, \$557,167).
- CLCRF Project Grant (2014): ‘Morpholino Therapy for Childhood Cancer’ (Beesley AH, \$113,135 over 1 year).
- CLCRF Project Grant (2014): ‘Finding the Most Effective Therapies for Midline Carcinoma’ (Beesley AH, \$111,637 over 1 year).

Publications A/Prof Beesley (2011 – 2015):

Stirnweiss A, McCarthy K, Oommen J, Crook M, Hardy K, Kees UR, Wilton S, Anazodo A, **Beesley AH**. Novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma. *Oncogenesis* 2015 (Accepted Sep 2015).

Yadav BD, Samuels AL, Wells J, Anderson D, Cole CH, **Beesley AH**, Kees UR & Lock RB. Mechanism of resistance to induction therapy in paediatric T cell acute lymphoblastic leukaemia (Anticipated submission Feb 2016).

Carter T, Charles AK, Murch AR, **Beesley AH**, Kees UR. A retrospective review of NUT-midline carcinoma prevalence at a Western Australian Paediatric Hospital (Anticipated submission March 2016).

**Beesley AH\***, Samuels AL\*, Yadav BD\*, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR, Lock RB. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia [\*joint first-authorship]. *Blood Cancer J* 2014;4:e232.

**Beesley AH**, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW, Arndt G, Charles AK, Cole CH and Kees UR. Comparative drug screening in NUT-midline carcinoma. *Br J Cancer* 2014;110(5):1189-98.  
Samuels AL, Heng J, **Beesley AH**, Kees UR. Bioenergetic modulation sensitises acute lymphoblastic leukaemia cells to glucocorticoids. *Br J Haematol* 2014;165(1):57-66.

**Beesley AH**, Firth MJ, Anderson D, Samuels AL, Ford J, Kees UR. Drug-gene modeling in pediatric T-cell acute lymphoblastic leukemia highlights importance of 6-mercaptopurine for outcome. *Cancer Res* 2013;73(9):2749-59.

Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, Kees UR, **Beesley AH**. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. *Oncogene* 2013;32(39):4664-74.

Francis RW, Thompson-Wicking K, Carter KW, Anderson D, Kees UR, **Beesley AH** (2012). FusionFinder: A tool to identify expressed gene fusion candidates from RNA-Seq data. *PLoS One* 7(6):e39987

Kotecha RS, Ford J, **Beesley AH**, Anderson D, Cole CH, Kees UR (2012). Molecular characterization of identical, novel MLL-EPS15 translocations and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia. *Haematologica*. Sep;97(9):1447-50.

Funding:CLCRF Project Grant (Jan 2014 – Dec 2015)

Researcher:Associate Professor Alex H Beesley

Title:Effective Therapies for NUT Midline Carcinoma



NUT Midline Carcinoma (NMC) is a terribly aggressive cancer affecting both children and adults alike, and for which survival is typically less than one year.

There is currently no cure for NMC and yet we know from our experience with childhood leukaemia that cures for apparently fatal cancers can be developed. Current treatments for NMC have essentially been adapted from those used in other cancers but this approach clearly is not working.

There are a large number of ‘conventional’ chemotherapy drugs available for doctors to treat such patients, but to date there has been no evidence to

guide them as to which might be the most effective. There is also growing evidence that some drugs used in non-cancer diseases (e.g. metabolic disorders), may be effective against tumours.

Thanks to the support of the CLCRF, we have now expanded what was originally a small collection of three NMC cell lines derived from patients treated at Princess Margaret Hospital, to a total of 12 such cell lines – the most comprehensive collection of NMC cell lines in the world.

By studying these lines we have learnt that NMC is comprised of at least five distinct genetic subtypes, and this is likely to have important

implications for drug therapy and clinical outcomes.

In collaboration with the Children’s Cancer Institute in Sydney we have now tested these cell lines against a large number of conventional and novel drugs and identified the types of therapy that seem to be most effective.

The data from this screen have already revealed surprising results, in that certain drugs that were thought to be highly effective in this disease are apparently not effective in every NMC subtype.

This has important clinical ramifications since this drug class is now in clinical trial for NMC. The data also support



our previously published work suggesting that the drug flavopiridol may be an attractive chemotherapy in this disease, since it has so far proven to be effective in all NMC cell lines tested; in a parallel we are currently examining mechanisms of resistance to this drug using a model system that we have previously established in the laboratory. Finally, we have observed highly

significant correlations in the efficacy of particular pairs of drugs, suggesting that their combination in the clinic may be more effective than current approaches for the treatment of NMC.

In partnership with the Drug Discovery Unit of Telethon Kids, we are also testing novel peptide therapies that show potential for targeting the molecular

defect driving NMC. In 2016 we intend to integrate all of our drug profiling data with the extensive molecular and genetic data we have now accumulated on our NMC cells, to identify the key biological pathways driving this dreadful disease and the most promising therapy approaches.

**Funding:** CLCRF Project Grant (Mar 2014 – Mar 2016)  
**Researcher:** Associate Professor Alex H Beesley  
**Title:** Morpholino Therapy for Childhood Cancer



Patients with NUT midline carcinoma (NMC) share a common genetic feature, which is a specific re-arrangement of the DNA within the cancer cell. Whilst this abnormality contributes to driving the disease, it also represents an Achilles heel because it can be used as a ‘target’ to design specific therapies i.e. drugs that attack the cancer cell but leave healthy cells alone. In 2014 & 2015 we worked with Prof Steve Wilton from Murdoch University to develop a novel therapy designed to target this genetic abnormality.

This approach uses drugs called ‘morpholinos’ that interfere with the way genes are expressed in the cell and Prof Wilton has successfully pioneered this approach as a genetic therapy in the field of

muscular dystrophy. The use of these agents in our NMC lines has revealed unexpected information about the ways in which the NMC gene can be expressed. Specifically, we have managed to induce a new variant of the NMC gene that can be expressed under certain conditions.

Remarkably, in a patient diagnosed last year at Sydney’s Children’s Hospital we were able to confirm this variant as an independent clinical subtype. Tragically this patient, a teenage girl, passed away only three months after diagnosis, demonstrating the voracity of the disease.

Working closely with her doctors we have been able to generate a cell line from this patient’s tumour with which to further study its biology,

resulting in a joint publication that has just been accepted by the journal *Oncogenesis*.

With this discovery we now know that there are at least five distinct molecular subtypes of NMC, as defined by the structure of this particular genetic feature, and we also know that they respond differently to chemotherapy drugs. However, we do not yet understand the full biological significance of these different subtypes, nor what determines these drug sensitivities.

To unravel this question we have now sequenced the full genetic code of our NMC cell lines and patient specimens. Over the last few months we have been using bioinformatics to analyse this information and thus identify the critical features driving



the disease; in 2016 we will then perform the necessary laboratory experiments to validate these findings. This approach will be integrated with drug-sensitivity data to yield a comprehensive map of the molecular genetic landscape of NMC and the biological pathways that are the most promising as targets for future therapies.

**Funding:** Woolworths Research Fellowship (2012 – 2015)  
**Researcher:** Dr Mark N Cruickshank  
**Title:** Identifying Molecular Abnormalities in Childhood Leukaemia to Improve Treatment



Dr Cruickshank has been employed within the CLCRF Laboratory in the Division of Cancer and Leukaemia Research since 2012, and was awarded the Woolworths CLCRF Research Fellowship. This Fellowship has enabled Dr Cruickshank to conduct research aimed at (1) identifying novel drugs for the treatment of high-risk infant leukaemia patients and (2) genetic mechanisms underpinning disease.

Dr Cruickshank has also continued researching genetic determinants of paediatric leukaemia and drug resistance. As part of his Fellowship, Dr Cruickshank has been involved in experimental design, data analysis and manuscript preparation for projects on infant ALL and childhood ALL, detailed under the CLCRF Triennial Block

Grant. The long-term vision of these research aims are toward detection of genetic biomarkers that are predictive of drug responses, thus empowering clinicians with new molecular prognostic tests and novel drugs, to design personalised therapies to cure this disease.

While many types of childhood leukaemia have shown remarkable improvements in patient survival (now up to 95%) over the last twenty years, infant leukaemia remains challenging to treat, with low survival (~30%) of the very young patients and significant morbidity for survivors.

Our drug screening studies have utilised patient specimens and cell lines grown in test tubes derived from these leukaemia

samples. In collaboration with the Children’s Cancer Institute Australia, we have interrogated the efficacy of over 150 novel drugs including FDA-approved cancer chemotherapies and additional “targeted” therapeutics that are currently in clinical trials for biologically related cancer sub-types.

These drugs represent the “next-generation” of therapeutics that are designed to target vulnerabilities specific to cancer and therefore are less toxic against normal cells with reduced patient side effects.

In addition, we have examined the interaction of selected novel drugs and current backbone therapies. Indeed, any novel drugs that are progressed to the clinic are likely to be introduced in such combinations. We have identified specific drug



combinations that function synergistically, but have also identified drug combinations that, in some patients, show adverse interactions. Therefore, we have been able to demonstrate that some drug combinations are consistently effective in killing infant leukaemia cells, while other drug combinations interact adversely to reduce their efficacy in some patient leukaemia cells. These results have been presented to members of the Children's Oncology Group for consideration of therapies to be included in clinical trials.

Our genetic characterisation of infant leukaemia has utilised state-of-the art "genomic" technologies, providing comprehensive characterisation of genetic differences specific to infant leukaemia patients. Indeed, the genetic cause of infant leukaemia has remained elusive, even though genomic sequencing technologies has identified many genes driving paediatric and adult cancers.

Dr Cruickshank has been testing the hypothesis that gene mutations inherited from both parents are necessary to drive disease, even though these gene mutations do not cause disease in each of the parents.

We have identified a panel of "defective" genes in infants with leukaemia that are well known as cancer predisposition risk genes. These include (1) genes that play a crucial role in repairing DNA damage; (2) genes that play a crucial role in controlling cellular growth and signalling; and (3) genes that control chromosome and

gene function ("epigenetic" regulatory genes). Moreover, we found that most infants carry defects in genes that cause hereditary cancer syndromes. Surprisingly, we found that in many cases, infant leukaemia cells express multiple defective genes that are known to underlie a variety of hereditary cancer syndromes.

Altogether, these results have identified for the first time, gene mutations associated with infant leukaemia that could help explain why this cancer is so aggressive and difficult to treat. Importantly, these results also pin-point potential vulnerabilities in the infant leukaemia cells that could represent new drug-targets.

The unique resources generated by the leukaemia team, including patient specimens and cell lines, are also being used to identify specific genes that are altered in infant and childhood leukaemia and which may confer resistance to conventional therapies.

These studies have identified potential 'biomarkers' that could predict drug sensitivity or drug resistance. In parallel, we have investigated the responses of these cells when treated with drugs that inhibit cellular processes affected by these gene mutations, finding highly variable responses among infant leukaemia cells from different patients. The 'biomarkers' under investigation include gene mutations, and alterations in chromosomes and levels of gene-expression. Thus, in addition to identifying novel

gene defects associated with infant leukaemia in patient samples, we have characterized cell lines to show that these patient samples can be grown in test tubes to directly assess the effect of these mutations on drug responses. These studies pave the way to test the efficacy of novel drugs on leukaemia cells with the mutations we have discovered.

Dr Cruickshank has successfully secured funding from the Telethon Kids Institute "Blue Sky Research Grant" scheme to identify novel drugs targeting these mutations.

Dr Cruickshank's work on paediatric leukaemia has identified a class of enzymes that may be involved in resistance to the drug flavopiridol. Using leukaemia cells selected for drug resistance, "genomic" analyses identified mutated genes that encode enzymes that process flavopiridol. Furthermore, analysis of gene expression induced by flavopiridol, identified enzymes involved in neutralizing and eliminating drugs that were activated after drug treatment. Taken together, these results have defined genes that may represent 'biomarkers' of drug resistance and targets for therapy in drug-resistant leukaemia.

Dr Cruickshank has been collaborating with Telethon Kids Institute Tumor Immunology Group Leader, Dr Jason Waithman, on a project with the aim of testing the possibility that immune cells can be harnessed to fight cancer. Thus far we have

developed a mouse model system that allows us to harvest mouse immune cells, treat them with drugs in test tubes, and test if the treated immune cells show improved abilities to fight cancer.

Thus far we have evaluated a panel of ten drugs and identified 2 structurally similar

compounds, both that inhibit cancer immunity in our model system. Since these drugs are promising novel drugs for many cancer types, our preliminary data suggests that these drugs should not be administered together with immune-based cellular therapies.

Dr Cruickshank has presented research from the Laboratory to community and scientific audiences in Australia, acknowledging the support from the CLCRF at each opportunity.

#### **Findings from research conducted during Dr Cruickshank's appointments have been presented in the following scientific forums and community groups:**

- WA Health Translational Network, Perth (2015)
- Telethon Kids Institute P4 Forum (2015)
- Telethon Kids Institute; Staff Retreat; Blue Sky Grant Presentation (2015)
- Australia & New Zealand Children's Oncology Group (ANZCHOG) Conference, Perth WA (2015)
- Telethon Kids Institute Children's Cancer Centre Forum (2015)
- Telethon Kids Institute; Discussion and Technical Seminar Series, Perth (2014)
- Children's Leukaemia & Cancer Research Foundation meeting (2014)
- Australian Bioinformatics Conference (2014)
- The 'Beyond the Genome' Conference, San Francisco, USA (2013).
- The American Society for Human Genetics, Boston, USA (2013).
- Cancer Epigenomics Cell Symposium, Sitges, Spain (2013)
- Telethon Institute for Child Health Research Seminar, Perth (2013)
- Perth Cancer Club, Perth (2013)
- Children's Leukaemia & Cancer Research Foundation meeting (2013)
- Lorne Genome (2013)
- WA Genomics & Epigenomics interest group, UWA, Perth (2012)



## Publications Dr Cruickshank (2011 – 2015):

**Cruickshank MN**, Ford J, Anderson D, Kotecha R, Cole C, Kees UR: Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of Romidepsin. Submitted manuscript to Cancer Discovery.

**Cruickshank MN**, Gout AM, Kotecha RS, Ford J, Carter KW, Heng J, Cole CH, Bosco A, Lassmann T, Kees UR: Frequent co-expression of rare alleles at loci associated with human genetic instability disorders in MLL-rearranged infant acute lymphoblastic leukemia. 2015 Manuscript in preparation for American Journal of Human Genetics.

**Cruickshank MN**, Mason R, Fenwick E, Karimi M, Abraham LJ, Ulgiati D: Notch signaling regulates activity of the human Complement receptor type 2 (CR2/CD21) gene. 2015 Manuscript in preparation for Cellular Signalling.

**Cruickshank MN**, Dods J, Fenwick E, Karimi M, Rae A, Holers VM, Abraham LJ, Ulgiati D: Tandem E-box motifs control human Complement receptor 2 (CR2) promoter activity via RP58, E2A, USF proteins and localized chromatin accessibility. 2015 The International Journal of Biochemistry and Cell Biology 2015 Jul;64:107-19.

**Cruickshank MN**, Oshlack A, Theda C, Davis PG, Martino D, Sheehan P, Dai Y, Saffery R, Doyle LW, Craig JM: Analysis of epigenetic changes in survivors of preterm birth reveals the effect of gestational age and evidence for a long term legacy. Genome Medicine 2013, **5**:96.

Martino D, Loke YJ, Gordon L, Ollikainen M, **Cruickshank MN**, Saffery R, Craig JM: Longitudinal, genome-scale analysis of DNA methylation in twins from birth to 18 months of age reveals rapid epigenetic change in early life and pair-specific effects of discordance. Genome Biology 2013, **14**:R42.

Jablensky A, Angelicheva D, Donohoe GJ, **Cruickshank MN**, Azmanov DN, Morris DW, McRae A, Weickert CS, Carter KW, Chandler D, et al: Promoter polymorphisms in two overlapping 6p25 genes implicate mitochondrial proteins in cognitive deficit in schizophrenia. Molecular Psychiatry 2012, **17**:1328-1339.

**Cruickshank MN**, Pitt J, Craig JM: Going back to the future with Guthrie-powered epigenome-wide association studies. Genome Med, 2012, **4**: 83.

Gordon L, Joo JE, Powell JE, Ollikainen M, Novakovic B, Li X, Andronikos R, **Cruickshank MN**, Conneely KN, Smith AK, et al: Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. Genome Research 2012, **22**:1395-1406.

**Cruickshank MN**, Karimi M, Mason RL, Fenwick E, Mercer T, Tsao BP, Boackle SA, Ulgiati D: Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21). Molecular Immunology 2012, **52**:165-173.

## DONATIONS \$100 & ABOVE 2014/2015

Many generous people and organisations gave to the Foundation during July 2014 - June 2015. We have tried to make the following list as accurate as possible but please forgive us if we have omitted details of your gift. Space does not permit us to list the numerous other donations given.

**Ursula R. Kees**  
**Alex H Beesley**  
**Mark N Cruickshank**

**25 November 2015**





## 2015 Teen Glass Slipper Ball

**A**

A Sheer Delight  
 Ace Design & Print  
 Addison Graham  
 Adegas Felipe  
 Advanced Solutions International  
 (Asia Pacific)  
 Afu Joshua  
 Ahern Paul  
 Alcoa of Aust Ltd  
 Allanson Brian  
 Allen Elizabeth  
 Allen Michael  
 Allen Wayne  
 Ambrose Russell  
 AMD Chartered Accountants  
 AMP Services Ltd  
 Anderegg Nicole  
 Anderson Alex & Sandra  
 Anderson International  
 Anderson Kimon & Sondra  
 Andrew Lavinia  
 Angi G & PA  
 Astone Joe & Ivy  
 Australian Protection Services  
 Australian Unity  
 Austvending Pty Ltd (SA)  
 Autobahn

**B**

Baker Family  
 Bakers Phil  
 Bamford William  
 Barnett John  
 Barrett-Lennard BR  
 Bartoli Giorgio  
 Batchelor Roy  
 Bathgate RM & AJ  
 Bayswater Senior Citizens Assoc  
 Beacham Gareth  
 Beamond Caroline  
 Beccegato Alessia  
 Bee Valerie  
 Beldina P/L  
 Bell Ian  
 Bellotti Danny & Rita  
 Bentel Dr Gary & Erica  
 Bentley Jan  
 Berinson Joseph & Jeanette  
 Bew Eric  
 BHP Billiton Universal Giving  
 Program  
 Bhrara Tanuja  
 Bibra Lake IGA Xpress

Bilick Dione  
 Birch Garry  
 Bissaker Adam  
 Blaxell Shirley  
 Boar Swanp Campdraft Club  
 Boulton Brian  
 Boykett Robert  
 Branchi Robert  
 Brenner Matt  
 Bridges Darren  
 Brockway Joyce  
 Brooker Adam  
 Brooker Shane  
 Brookmin P/L  
 Broom Kevin & Bev  
 Brothers As One West Coast Albany  
 Brown Glen  
 Brown Karen  
 Brown Paul  
 Brown Marley & Morris  
 Bruce Justin  
 Bruns WP (Peter)  
 Busselton Old Time Dance Inc  
 Buttfield Jan

**C**

Cabaret Gaming P/L  
 Carling Rose  
 Carman Chris  
 Cattach Family - Harvey  
 Causier David & Susan  
 Cavanagh Christine  
 Chaloupe Clare  
 Chan Kwan  
 Chapman Derek  
 CHEP Australia  
 Chicken Treat - Australind  
 Christ Church Grammar - Romsey  
 House  
 Cicerello Jan  
 City of Subiaco  
 Clark Ramon & Rosalind  
 Cohan D  
 Colley Valda  
 Coolup Campdraft Club Inc  
 Cooper Brenda  
 Cooper Pery  
 Cornerstone Lodge No 368  
 Country Womens' Assoc - Grass  
 Patch  
 Crema Courmet Coffee Roasters  
 Cresswell Richard  
 Criddle Peter  
 Crook Rosalie  
 CWA of WA (Inc) Bayswater Branch

**D**

Dalmain Primary School  
 Damaya Designs  
 Daniels Jan  
 Davies Drew  
 Day Hazel  
 De Chiera PS & DM  
 De Mattia Julian  
 De Vos BJ & DM  
 Deane Jill  
 Dekker Robert & Ingrid  
 Denis Gimblett & Associates  
 Dept of Agriculture  
 Desiree Dance Academy  
 Detiuk Michael & Georgina  
 Di Candilo G  
 Dilworth Nerida Dr  
 Dobson Malcolm  
 Donnes Kevin  
 Donnybrook District High School  
 Drillshop P/L  
 Dubois Ian  
 Dunning Vaughan  
 Dunstan FM

**E**

EBM Insurance Brokers P/L  
 Edwards John  
 Elliott Mary  
 Ellis Anne  
 Ellis Barry & Sue  
 Entertainment Publications  
 Evolve Research & Consulting

**F**

Fahl Christina  
 Fairchild Audrey  
 Falconer Peter & Moira  
 Fardon Andrew & Jackie  
 Fergusson Brendan & Helena  
 Flinders Square Dental Surgery  
 Floyd Margaret  
 Foote Allan & June  
 Foster Stephen & Elizabeth  
 Foulds Ainsley  
 Fremantle Sailing Club  
 Froude Winifred  
 Fry Wendy

**G**

Galati Cono & Trudy  
 Gale Brian & June  
 Galleria Toyota  
 Galvin James & Gabrielle  
 Gaunt Joy  
 Gavranic Angeline

Geers Lesley  
 George Iniga  
 Gibson Luke  
 Gilbert Vanessa  
 Gill Kevin & Cheryl  
 Ginbey Robert & Marie  
 Golding Graham & Jenny  
 Gooding D & M  
 Gordon Ron  
 Graham Rory & Christine  
 Grant-Webb Teneal  
 Great Southern Grammar  
 Green H  
 Green Ricky  
 Greenham Tim & Sue  
 Grill'd Subiaco  
 Groen Stephen & Therese  
 Grosser Kerry  
 Guilfoyle Sarah

**H**

Haederle Mike & Judi  
 Haig John  
 Hall Anthony  
 Hambley Bill & Rita  
 Hamilton Robert  
 Hampson Kerrin  
 Harmelin James  
 Harvey Italian Club  
 Haselhurst A  
 Henley R  
 Hesketh John & Barbara  
 Hew Patrick  
 Hick GB & NE  
 Higgs William  
 High Wycombe Public Library  
 Hill Charles & Joan  
 Hill Stan & Beryl  
 Hislop Brett  
 Hogbin William  
 Holden Accountants  
 Holding Richard  
 Hollis Alfred  
 Holmes Naomi  
 Hooper David  
 Hosch Family  
 Hosford Kevin & Angelina  
 Houghton Lance  
 Houghton Wines  
 Howarth Family  
 Hudson Road - Foodlands  
 Hughan John  
 Hulls DC & JR  
 Hume Building Society Ltd  
 Hunt Greg & Nia  
 Hutchings Les & Alice

Hutchison John & Norah  
 Hyde Rob & Rosemary

**I**

Ivory Valma

**J**

Jahn Richard  
 James Pauline  
 Jandakot Primary School  
 Jarosek Frank  
 Jennings Andrew  
 Jeremy's Exclusive Butchery  
 John Septimus Roe Anglical  
 Community School  
 Johnson-Smith Khara  
 Jordan Marion  
 Jupp Allan & Cheryl

**K**

Kane Community Foundation  
 Karosas Aurimas  
 Katie Virgo Dance Academy  
 Keane Brian  
 Keil Christopher  
 Kennedy Heide  
 Keystart Home Loans  
 Khazaly Kam  
 Kieran Andrew  
 Killoh Jack  
 King Barbara  
 Kingsley Retirement Village  
 Kitchen John & Mary  
 Kitto Angus  
 Knight Eric  
 Knox Christina  
 Kotevski George

**L**

Lai Yin Yat & Tze Yien Wee  
 Landsdale Forum News  
 Lane John, JP  
 Langer Family  
 Langsford Kim  
 Larke Graham & Althea  
 Lawler Michael  
 Lawrence Business Management  
 Lee John  
 Leighton  
 Leppard Todd  
 Letari Paul  
 Leverington Glenda  
 Lewis Roderick  
 Liddelow Glen & Alessandra  
 Lilleyman Jill  
 Lions Club of Binningup Waters

Lions Club of Boyanup  
 Lions Club of Capel  
 Lions Club of Coonamble Inc  
 Lions Club of Cowaramup  
 Lions Club of Falcon  
 Lions Club of Leeuwin (Inc)  
 Lions Club of Margaret River  
 Lions Club of Ocean Reef Inc  
 Lions Club of Serpentine-  
 Jarrahdale Inc  
 Lions Club of Waroona  
 Lissiman Terry & Cindy  
 Locke Victor  
 Lodge Golden Beacon No 14  
 WAC  
 Love Carl  
 Lychlander Sheila  
 Lydon Larry & Isabell  
 Lyons Joan

**M**

Maliunas Coral  
 Mallabone Peter & Retallack Joan  
 Mandurah Over 55's Canoe Club  
 Inc  
 Marchant Family  
 Marella Nominees P/L  
 Margaret Down Fdn for  
 Disadvantaged Children  
 Marshall Robert & Alene  
 Martin Maureen  
 Maslin DM  
 Mastai Robert & Anna  
 Matthews Maureen  
 Mauremont Resources P/L  
 Mazzachelli Don  
 McCarthy Brian  
 McClurg Greg  
 McClymont Frank  
 McCorkill Dr Ron & Michelle  
 McCormick Dorothy  
 McCusker Charitable Foundation  
 McDonald Ian & Penny  
 McDonald Tom  
 McDonnell B  
 McGlynn Joshua  
 McGrath Alan & Susanne  
 McLarty Leigh & Nicole  
 McLean Amanda  
 McMahan Christopher  
 Melville Scrabble Club  
 Michales Paul & Effie  
 Mills Alistair  
 Mills Jenny  
 Mincherton Glyn  
 Mining People International P/L



Morley Gaels Gaelic Football Assoc  
Morrison William  
Morton EL & D  
Mountain Lara  
Muir Darryl  
Munday Eric

**N**  
Nahler Regine  
Nail Plus+  
Nardone Paul  
National Insurance Brokers Assoc of WA  
Naylor Robert  
National Lifestyle Villages P/L  
Neillings Robert & Anne  
Newton Tony  
Nexus Risk Services  
Ng MS & LT  
Nikolovski Oliver  
Nixon Bros  
North Peter  
Norton Daniel  
Nottle Pat

**O**  
O'Connor Lunch Box  
O'Connor Primary School  
Ong Irene  
O'Reilly Jody  
Owen MA & JA

**P**  
Page Jamie & Kerry  
Panaia Mario  
Parkland Villas - Tuesday Afternoon  
Craft Group  
Parry David  
Pearce Catrina  
Pearce Natasha  
Pearson Ann-Marie  
Pentelow AM  
Philp Betty  
Pintabona Charles & Sharon  
Pizzuto Mark  
Platt Wayne  
Plunkett Fiona  
Pollard Steven  
Pomery Kiri  
Pool Wayne  
Popsicle & Co  
Presbyterian Ladies' College  
Presence On Preston  
Prindiville Terrence  
Professionail - Centro Galleria  
PwC - Cool Night Classic

**Q**  
QBE Australian & New Zealand  
Quadrant Energy Australia  
Quality Printers & Cartridges P/L  
Quinn Jayne

**R**  
RAAFA Estate Club Merriwa  
Volunteers Group  
Rainbow Ebony  
Raspa Neil & Emily  
RCWP Trust  
Reed Marcia  
Rees Wynn  
Repeat Offender  
Richards Elizabeth  
Richards Pamela  
Ritz Café  
Rix Michael & Frances  
Road Trains of Australia  
Rodoreda Greg & Michelle  
Roe Pauline  
Rose Robert H  
Rotary Club of Busselton  
Rotary Club of Harvey  
Rotary Club of Margaret River  
Rotary Club of Pinjarra  
Rotary Club of South Bunbury  
Row Shirley  
Rowan Zenobia  
Rowley Eleanor  
Rutherford David  
Ruyi Enterprises P/L

**S**  
Sanderson Lance & KG  
Saunders Joan  
Saville Peter & Sandra  
Sawyer Steven  
Sceales Robert  
Schulze Dean  
Sears Edward  
Sears EJ  
Segler Mark  
Setter Troy  
Seymour Clive  
Shean P/L  
Sheldrake Sophie  
Shephard Glenice  
Shepherd Charles  
Shreeve & Carslake P/L  
Silsbury Robin  
Sim Paula  
Simms Bradley  
Sindoni Robert

Skinner Joy  
Slatter Brian  
Small Barry & Jeanette  
Smirk Richard  
Smith Janine  
Smith Wayne & Nancye  
Sound Tax & Accounting  
Southern River Progresss Assoc  
Sparkle Dental  
Spectra Business Partners  
Spencer Colin  
St Andrew's Catholic Primary School  
St Mary's Anglican Girl's School  
Stagecraft P/L  
Stan Perron Charitable Foundation Ltd  
Stancic Jasmina  
Stanford Diane  
Stanley Fiona Prof, AC  
Statewide Bearings  
Stephenson Ian & Sonia  
Stevens Steven  
Stevenson Dorothy  
Stewart Lee & Co Rural Marketing  
Sticky Fingers Candy Store  
Stojanovich David  
Stone Jenni  
Stuchbury Mark & Laura  
Suen YM  
Summers Margaret  
Sweet Success Personal Training  
Syd Matthews & Co P/L

**T**  
T.G.I.F. Line Dancers  
Taaffe Dean & Katrina  
Taddei Nat  
Tagliaferri Stephen  
Taylor JR & MM  
Terriaca Felicia  
Terwindt Con & Anna  
The Crema Cruiser  
Think Pink Realty  
Thompson Diana  
Thornlie Bowling Club  
Thornton Alan & Danielle  
Tischhauser Peter & Linda  
Toohey John  
Toolmart Australia Ltd  
Torelli Rita  
Trickett Christine  
Troncone Fred & Susan  
Tuite Helen  
Turner Mark

**U**  
Underwood Leonie  
United Fundraisers

**V**  
Van Dijk H & C  
Vanguard Solutions P/L  
Venables Stephen  
Vernon MJ  
Vieira John  
Vogel Retro  
Vojkovich John  
Von Perger M

**W**  
WA Primary School Football Championships  
Walker Family Trust  
Walker Richard  
Walker Tracey  
Walsh Glass  
Wannberg Family  
Warner Amy  
Warner Kelvin  
Waterlily Beauty & Makeup Studio  
Webb Graham  
Wellard Group Holdings P/L  
Welton Lyneve  
West Brothes Sport Leisure  
Westside Golf Club  
Wheeler Geoff  
Wheeler Greg  
Whiffin David  
White Ron & Cheryl  
Wieclaw Josef  
Wiklund Mark  
Wilborn Bernie  
Wilkinson Trevor  
Willetton Senior High School  
Williams Rosemary  
Willis Sally  
Wilson Brian  
Wood Brendon & Margaret  
Wood Daniel & Marshall-Wood Holly  
Wood Simon & Stacey  
Woodley Elizabeth  
Woodvale Primary School

**Y**  
Yu Bi-Yuy

**Other Support:**  
Allion Legal  
Absolute Edge Media P/L  
BBC Entertainment  
Belmont Oasis Leisure Centre  
Bluck Sue  
Boar Swamp Campdraft  
City of Subiaco  
Claremont Art Framers & Gallery  
Clements Chloe  
Dunn Trudy  
Entertainment Publications  
Everyday Hero  
Garrett Caitlin  
Go Fundraise  
Hello Call Centres  
Houghton Winery  
Keep The Flame Alive Volunteer Team  
Kiely Sharon  
Langer Justin – Patron  
Lord Mayor, Hon Lisa M Scaffidi - Ambassador  
McKenzie Caroline  
McLarty Family  
My Cause  
Quality Printer Cartridges  
Quik Impressions  
Regal Theatre  
Repeat Offender  
Royal Life Saving Society of WA  
Telethon Kids Institute  
Top Shelf Web Design  
Twisted Balloons





# MEMBERS AS AT THE 30/06/2015



## A

A'Court Susan  
Agostino Melina  
Ahern Muriel  
Alban Anselma  
Alexander Andrea & Gordon  
Allen Ebony  
Allen Elizabeth  
Allen Family  
Al-Saffar Karim  
Anderson Kimon & Sondra  
Anthony Ted  
Antiskid Pty Ltd  
Anzellino Dom & Rosa  
Archibald Lesley  
Arnold Geoffrey  
Astone Joe & Ivy  
Aubin Paula

## B

Bailey Philip  
Baker David Dr  
Baker Family  
Bakers Phil  
Ballantyne Patricia  
Barbas Family  
Barnett John  
Barrett Margaret  
Barrett-Lennard BR  
Batchelor Roy  
Bate Warren & Mandy  
Bauer Christian  
Bayliss Steve  
Beake Jim  
Bee Valerie  
Beer Campbell

Bell James  
Bender Elsie  
Bender Raymond  
Bender Sophie  
Bennett Michael & Vicki  
Bennett Peter & Angela  
Bennett Iris  
Bentley Jan  
Bingham Julie  
Blackers G  
Blampey Matthew  
Bombardieri Patricia  
Boogaard Annette & Austin Ken  
Boucalt Gary  
Boulton Brian  
Bowater Valma  
Boyd James  
Bradshaw Maria  
Bradshaw Elizabeth & John  
Brand Beth  
Brassington John  
Bridson Suad  
Brockway Frank  
Brodie-Hall R & C  
Broom Kevin & Bev  
Brown Amber  
Brown Gerry & Thea  
Brown Carlene  
Brown Peter  
Brown Philip  
Brown Colin & Glenice  
Bruce Charlotte & Rob  
Bruce Justin  
Bruce Kristy  
Bruce Philip Life Member  
Bruce Family  
Budd Joy

Bunn Tania & Loren  
Burdge Phillip  
Burgess Donald (Canada)  
Burn Margaret  
Burns Faith  
Butcher Doug  
Butler Robyn  
Buttfield Jan  
Byers Dorothy  
Byrne Bridy, Jnr M  
Byrne Grady, Jnr M  
Byrne Lily, Jnr M  
Byrne Murphy, Jnr M  
Byrne Riley, Jnr M  
Byrne Troy, Jnr M

## C

Cairns Bruce & Debra  
Calleja John  
Cantone Joseph  
Carpenter Connie  
Carr Daniel & Kasey  
Carvajal Tony  
Cattach David & Jenny  
Cattach Brent  
Cattach Geoff, Life Member  
Cattach Stewart  
Causier David & Susan  
Celisano Carlo  
Chandler Geoff  
Chapman George & Lucy  
Chapman Janine  
Chapman Family  
Charles Foti Business Services  
Chong Bryan - Jnr M  
Christian Bret  
Clark Michael & Jane

Clark Robert & Sue  
Clark Rowan  
Clarke Wayne  
Cleave A & B  
Clifford Alistair  
Cochrane Debi  
Cocking Barbara  
Cole Catherine Dr  
Collings Arlene  
Colwill June  
Condello Ralph  
Connor Judith  
Cooke John  
Coote Annette & Kevin  
Cotter Carolyn & Gary  
Couzens Kathleen  
Covich John  
Crawley Nigel  
Criddle Jack  
Crook Rosalie  
Crosby Edith  
Crowle Peter

## D

Daljac John  
Dalwood Greg  
Daniels Jan  
Davidson Sandra  
Davies Lesley  
Davis Lesley & Tony  
De Chiera PS & DM  
De Gruchy Dorothy  
De Nooyer Len  
De Petra Dawn & Genelle  
Delroy MD Neil  
Detuiuk Lloyd Kenda & Tanya  
Detiuk Michael & Georgina  
Detiuk Nicholas & Yvonne  
Deuter Carol  
Devine Kerry & Catherine  
Di Biase Bianca  
Di Candilo Steel City  
Dickson Stuart & Jennifer  
Di Masi L & E  
Dodd E F  
Downe Rod  
Draper Stephen & Karen  
Duane Bec  
Ducey Gerry & Beryl  
Dunham Richard & Kathleen (USA)  
Dunning Vaughan  
Duxbury Helen  
Dwyer Amy  
Dyson C  
Dzal Vicky

## E

Edmunds BK & DM  
Edwards Murray  
Elliott Mary  
Elliott Margaret  
Ellis Barry & Sue  
Ellis Steve & Doreen  
English Skye May (Jnr)  
Escott Brenda

## F

Faed Angus & Tonia  
Fahrner Helke Dr  
Falconer David, Leanne & Family  
Falconer Moira  
Falconer Peter, Life Member  
Fardon Andrew & Jackie  
Farquhar Sharna  
Fawcett Bob & Jan  
Fawcett KE  
Fels Brian  
Fergusson Helena & Brendan  
Field Donna  
Fiorenza Tony  
Fisher Kellie  
Fitzgerald John  
Fitzpatrick Robyn  
Flavel Don  
Flint Monica  
Flis Family  
Foote June & Allan  
Ford Jette & Peter  
Forrest Stewart  
Fowler Jennifer  
Francis Rosslyn  
Fraser Glen  
Fraser Anne & Neil  
Fraser Ciara, Jnr M  
Fraser Michael, Jnr M  
Frawley M & S  
Frossos Family  
Frost Petra  
Froude Winifred

## G

Gabelich Debra  
Galati Cono & Trudy  
Galati Vincent & Pamela  
Garas Monier  
Garner Family  
Gasparini Ivan  
Geddes David & Charlotte  
Gee Marie  
Genovese/ Fox Family  
George Janet

Germain Terrence  
Germs Leanne  
Gerschow Otto  
Gibson Lisa  
Giglia Lou & Maria  
Gilbert Family  
Gilbert Vanessa  
Gill Kevin & Cherryl  
Gilna Michael & Linda  
Ginbey Robert & Marie  
Giorgio Carmela  
Glass Thelma  
Gobbart Rhona  
Gobby Geoffrey  
Godfrey Allan & Fiona  
Godfrey Greg & Linda  
Goetz Marilyn  
Gordon Graeme  
Goullos Philip  
Goyder John & Pam  
Graham Rory & Christine  
Graham Valerie  
Grant Rosemary  
Gray Jill  
Green Bobbie  
Greenham Tim & Sue  
Grosser Kerry  
Gucciardi Tony & Lisa  
Gunellas Yvonne

## H

Haederle Mike & Judi  
Hagan Merv  
Haig John  
Hall Cassie, Jnr M  
Hall Family  
Hambley Bill & Rita  
Han Edward & Francis  
Hanley Garry  
Hanssen Gerry  
Hargrave Steve  
Harper Margaret  
Harper Peter, Life Member  
Harris Eileen  
Harris Murray, Helen & Justin  
Hart Linda & Roy  
Harwood Fran  
Hawley Dave  
Hayes Sharyee  
Haynes John  
Heal Eric & Judy  
Heal Valda  
Heenan Elizabeth  
Heil Adrian  
Herlihy Geoffrey  
Hesketh John & Barbara



Hewett Mitch  
 Hicks David & Pam  
 Hicks Gillian (UK)  
 Hiddlestone Kay  
 Hiddlestone Natalie  
 Hiddlestone Kay  
 Hill A  
 Hill Charles & Joan  
 Hill Roger  
 Hill Stan & Beryl  
 Hillaert Francoise  
 Hilton Lynette  
 Hogben Terry  
 Holly Grace & Tiny  
 Holman Leah  
 Holmes Martin  
 Horn Therese  
 Horrocks Megan  
 Hortle Jan  
 Howarth Family  
 Howe Suzanne  
 Howell Sue  
 Huggins Joanne  
 Hugo Chris & Amanda  
 Hutchings Brad & English  
 Cassandra  
 Hutchings Les & Alice  
 Hyde Rob & Rosemary

**I**  
 Ieraci Cosi & Casey  
 Ieraci Renae  
 Ieraci Stefan  
 Ieraci Tony & Lorna  
 Italiano Robert & Minnie  
 Italiano Harley, Jnr M  
 Italiano Tyson, Jnr M  
 Italiano Zak, Jnr M  
 Ivory Valma

**J**  
 Jackson Tanya & Trevor  
 Jackson Vicki & Neil  
 James Errol  
 Janiec Edward  
 Jarvis Stephen Dr  
 Jayawardena Shamal  
 Judy Jefferies  
 Jenkins Graeme  
 Jennings Brian  
 Jennings Ian & Val

Johnson Maureen Kay  
 Jones Clive  
 Jones Susan

Jones WB  
 Joyner Simon  
 Jupp Cheryl & Allan

**K**  
 Keane Brian  
 Kearns Gary & Wendy  
 Keeffe Faye & Phil  
 Keighran Dean  
 Kelly J  
 Kelly Linda  
 Kelly-Cook Danielle  
 Kenda Lloyd & Detiuk Tanya and  
 Family (Hong Kong)  
 Kenda Renato & Annette  
 Kerr Margaret  
 Kiernan Barbara  
 Kijak Eva Dr  
 King Barbara  
 Kinnear Brett & Christine  
 Kirkwood Kerrin  
 Kitchen John & Mary  
 Knight Jeffrey Dr  
 Koelen M & J  
 Kondhalker Prashant  
 Konigsberg Hilary  
 Kounis Kaye  
 Krikke Peter  
 Kumagai Hiromi

**L**  
 Lamb Phil  
 Lane, John (JP)  
 Langer Joy-Anne  
 Langer Ali-Rose, Jnr M  
 Langer Grace, Jnr M  
 Langer Jessica, Jnr M  
 Langer Justin, Patron  
 Langer Sue  
 Langer Sophie, Jnr M  
 Larke Graham & Althea  
 Lata Roshni  
 Lawrence Susan & Shaun  
 Laycock Ruth  
 Lazzarich Family  
 Le Page Michael & Maria  
 Lee John  
 Leeftang Cathriena  
 Liddelow Glen Dr & Alessandra  
 Lodge Robert & Gail  
 Lombardi Shirley  
 Love Murray  
 Loveridge Camilla & Gavin  
 Lovett Craig  
 Lowry Georgia

Lush Katelyn  
 Lychlander Sheila  
 Lydon Larry & Isabell  
 Lynch Emily  
 Lynch Andrew  
 Lynch Bruce & Glenda

**M**  
 MacDonald Kevin & Eileen  
 MacFarlane Kerry  
 Mackey Rob & Grace  
 MacLean Christine  
 MacLeod Jessie  
 MacLeod Patricia  
 MacPhail Duncan & Julie  
 Mainwaring Kiren & Kelli  
 Mancuso Maruzza  
 Manning Peter  
 Manuel Don & Pat  
 Marchant Family  
 Marinich Jeanette  
 Marra Rolando  
 Marron Bret & Jane  
 Marron Chelsea  
 Marsell William Dr  
 Marshall Marion  
 Martin Evelyn  
 Martin Robyn  
 Martin Sharon  
 Masarei John Dr & Marylee  
 Massara Family  
 Mathews Kerry  
 Matthews Daniel  
 Mathews Neville  
 Mathews Wendy  
 Mattia Renata  
 Maughan Chris & Olive  
 McAullay Darren  
 McCallum Family  
 McClymont Frank  
 McCorkill Ron Dr & Michelle  
 McCormick Dorothy  
 McCormick Steve & June  
 McCusker Malcolm, AO, CVO, QC  
 McDonald Ian & Penny  
 McEwen Amanda & Grant  
 McGinty Hazel  
 McGrath Warren  
 McKay Lex  
 McKenzies Auctioneers, Valuers  
 & Exhibitions  
 McNeill Pamela  
 Meenworst ME  
 Merillo Joseph & Elisma  
 Mignacca Sharon

Mignacca Emily, Jnr M  
 Mignacca Michael, Jnr M  
 Millband Margaret  
 Miller Rusty & Barbara  
 Miller Ted  
 Miller Ross  
 Mills Alistair Dr  
 Mills Jenny  
 Mills Nancy  
 Milner Warren  
 Milton Nui & John Dr  
 Mischin Michael MLC  
 Mitchell Colin  
 Mitchell Family  
 Mitchell Justine  
 Mitchell Margaret  
 Moir Sue  
 Morrissy Jenny  
 Moss Trisha  
 Muir Darryl  
 Muir Jon  
 Murray Wendy  
 Myers John

**N**  
 Nabbs David & Pam  
 Nabbs Declan, Jnr M  
 Nabbs Holly, Jnr M  
 Nabbs Sarah, Jnr M  
 Nabbs Sophie, Jnr M  
 Navarro Martin  
 Neillings Kaye  
 Newton Beth  
 Nolan Brendan  
 Norton Daniel  
 Noske Kim & Gillian  
 Nottle Pat  
 Nowland David & Susanne  
 Nunn Malcolm & Leanne  
 Nyenhuis Brigitte & Harry

**O**  
 Oldham Neil & Shirley  
 Oldham Tracey  
 Oliver Jean  
 Oliveri Antonio & Santina  
 O'Neill Lawrence  
 O'Neill Shane  
 Ong Jung Shen  
 Ong Siew Geok

**P**  
 Page Jamie & Kerry  
 Palmer Patricia  
 Panizza Rachel

Parker Judith AM DSJ  
 Parker Kane  
 Parker Michael & Cathrine  
 Parkin Peggy  
 Parry David  
 Partridge Terry  
 Paul Donnelle  
 Paulin Anthony  
 Payne A  
 Peaker Shirley  
 Pech Judith  
 Perkins Roy  
 Philp Ray  
 Pickett EF  
 Pickett Damian & Vanessa  
 Piggott Sam  
 Pike Vanna & Les  
 Pintabona Charles & Sharon  
 Pontre Securities Pty Ltd  
 Powell Sandra  
 Preece Christine  
 Preisler-Hansen Carl  
 Price Esther  
 Purcell Michael

**Q**  
 Quinn Judy  
 Quiñones Susanne

**R**  
 Ratcliffe Alan & Sue  
 Ratcliffe Sean  
 Rate Yvonne  
 Reed Brad  
 Rex Caroline  
 Reynolds Abby  
 Reynolds Dwayne – Drillshop P/L  
 Richards Celia  
 Richards Elizabeth  
 Rigali Daniel, Damien & Elia  
 (Gourmet Fresh Farms)  
 Rijkuris Teodors & Pixie  
 Riley Mary & Geoff  
 Rinaldi Brad  
 Roberts Carolyn  
 Robertson Ian & Cecily  
 Robins Mark, Jnr M  
 Robins Sarah  
 Robins Trudie Joy  
 Robinson Graeme & Priscilla  
 Rodoreda Greg & Michelle  
 Roebuck Simon  
 Roffey Scott  
 Rolliston Jack, Jnr M  
 Rolliston Linda

Rolliston Peter  
 Rolliston Samantha, Jnr M  
 Rolliston Tonya, Jnr M  
 Rose David  
 Rose Steven & Helen  
 Rossen Real Estate  
 Rotary Club of Bunbury  
 Rotary Club of Harvey  
 Rotary Club of South Bunbury  
 Rowan Zenobia  
 Rudd Kim  
 Russell Bill  
 Rutherford David  
 Ryan Nicholas

**S**  
 Salamone Rebecca  
 Sanders Luke  
 Sarti Rhonda  
 Savage Dean & Paulette  
 Schmid Charlie  
 Schneider Darren & Cheree  
 Schulze Dean  
 Scolaro Patricia  
 Scott Graham & Linda  
 Segal Leah  
 Seidelin Erik & Helen  
 Senior Sue  
 Sequeira Andre & Neicha  
 Shackleton Aaron  
 Sherry Colin & Lesley  
 Silbert Lindsay & Suzanne  
 Silsbury Robin  
 Sim Paula  
 Simons Eileen  
 Sinclair Family  
 Skinner James & Patricia  
 Skinner Joy  
 Skinner Samantha  
 Sladden Mark & Julie  
 Slatter Brian  
 Small Craig & Melanie  
 Smith Catherine  
 Smith Jim  
 Smith Masie  
 Smith Philip  
 Somes Jane  
 Spagnolo Family  
 Spalding Ivan  
 Spalding Maurie  
 Sparks Amanda  
 Spence Charles  
 Spencer J & E  
 Stanley Brian  
 Stanley Fiona Prof, AC



Starkey Lorraine & Stephen  
Steel Christine & Peter  
Stewart Annette & Tahlia  
Stokes Marie  
Stokman Gerda  
Stone Stephen  
Stopp Bryn & Nicole  
Stopp Shane & Hayley  
Stopp Todd & Orlagh  
Stopp Valerie  
Storrs Julia  
Stratton Veronica  
Street John  
Stuchbury Laura & Mark  
Sugg LW & AJ  
Sullivan Brian & Shelley  
Susomrith Pattanee  
Sutton Peter & Glenda

**T**  
Tassone Joseph  
Tate Noelene  
Tate Franklin  
Taylor Alan & Michelle  
Taylor JR Dr & MM Mrs  
Teague Cheryl  
Teague Trent, Jnr M  
Tedla Shewanesh  
Teraci Paul  
Terms Alexandra  
Terry Philippa  
Thomas Family  
Thomason Tony  
Thompson Melvyn & Carol  
Thornton Janine  
Trewren Edith  
Troncone Susan & Fred

Trouchet Terry & Barb  
Turner Glen  
Turner Jim  
Turner Keven Dr & Fay

**U**  
Udinga Jan & Alex  
Uros Deanne & Timm

**V**  
Vale Jo  
Valom Hendrik  
Van Burgel Gary, OAM, JP  
Van Der Lecq P & A  
Van Dijk B & C  
Van Duyn J & TD  
Van Mansum Jeanette & Paul  
Verbrugge Roger & Vanessa  
Villa Gillian

Vinar Family  
Vittino Ric & Jackie  
Vogel Reto  
Vogels Linda

**W**  
Wadsworth Jennifer  
Walker Richard G  
Wallace M-J  
Walters Barry  
Walton Drew & Amy  
Walton Judi  
Wannberg Family  
Wards Family  
Warn Rosalie  
Warner Amy  
Warwick Lorraine  
Warwicker Shirley

Webb Brian & Maxena  
Webster Claudia  
Webster Steven  
Weldt Godfrey  
Weldt Thekla  
Werner Patricia  
White Ron & Cheryl  
Wickham Gail & Graeme  
Wieclaw Josef  
Wigger-Smith Courtney  
Wilborn Bernie  
Williams Courtney  
Wilborn Ganesh, Jnr M  
Williams David & Kirsten  
Williams Rosemary  
Williamson Kim Life Member  
Williamson Jenny  
Williamson Jocelyn & Robert

Wilson Lorna  
Wilson Stephen Dr  
Winton Geoff  
Wolfe Jeanette  
Wong Joe & Dr Cheryl  
Wood Brendan & Margaret  
Wood David  
Wood Simon & Stacey

**Y**  
Young Duncan & Annie

**Z**  
Zuchner-Mogall Gisela





# Children's Leukaemia & Cancer Research Foundation (Inc)

## FINANCIAL STATEMENTS Year Ended 30<sup>th</sup> June 2015



CHILDREN'S  
Leukaemia &  
Cancer Research  
Foundation (Inc.)

Suite 3  
100 Hay Street,  
Subiaco WA  
PO Box 1118  
West Perth WA 6872

**Telephone**  
(08) 9363 7400

**Fax**  
(08) 9382 8798

**Email**  
admin@  
childcancerresearch.  
com.au

**Web**  
childcancerresearch.  
com.au

ABN 42 030 465 053

**Patron**  
Justin Langer

**Life Members**  
Geoff R Cattach AM  
Peter J Harper  
Peter Falconer OAM  
Phil Bruce


### STATEMENT BY THE COMMITTEE OF MANAGEMENT

The Committee Members have determined that the Foundation is not a reporting entity, and that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial report.

In the opinion of the Committee of Management, the accompanying financial reports:

1. (a) The accompanying Operating Statement gives a true and fair view of the surplus of the Foundation for the financial year; and  
(b) The accompanying Balance Sheet gives a true and fair view of the state of affairs of the Foundation as at the end of the financial year.
2. At the date of the statement there are reasonable grounds to believe that the Foundation will be able to pay its debts as and when they fall due.

This statement is made in accordance with a resolution of the Committee of Management and is signed by and on behalf of the Committee of Management by:

  
Executive Officer – Andrea Alexander

  
Treasurer – Kim Williamson

Date: 21/10/2015

The accompanying notes form part of the financial statements.





**INDEPENDENT AUDIT REPORT**

**To: The Management Committee, Children's Leukaemia & Cancer Research Foundation (Inc)**

**SCOPE**

We have audited the Financial Report for the Children's Leukaemia & Cancer Research Foundation (Inc) for the year ended 30 June 2015. The Management committee is responsible for the Financial Report.

Our audit has been conducted in accordance with Australian Accounting Standards. Our procedures include examination on a test basis, evidence supporting and other disclosures in the Financial Report. These procedures have been undertaken to form an opinion whether, in all material aspects, the Financial Report is fairly presented.

The audit opinion expressed in the report has been formed on the above basis.

**QUALIFICATION**


As is common with organizations of this type, it is not practical for Children's Leukaemia & Cancer Research Foundation (Inc) to maintain an effective system of internal control over donations and other fund raising activities until their entry in the Accounting Records. Accordingly our audit in relation to fund raising was limited to the amount recorded.

**QUALIFIED AUDIT OPINION**

In our opinion, except for the effect of such adjustments, if any as might have been determined necessary had the limitation discussed in the qualification paragraph not existed, the Financial Report presents fairly and in accordance with applicable Accounting Standards, the financial position of Children's Leukaemia & Cancer Research Foundation (Inc) at 30 June 2015.

**AUDITOR**

**Signature**



**Full Name**

**Nick Del Popolo, ACA**

**Address**

**9 Carrington Street, North Perth, WA, 6006**

**Phone**

**0419 922 776**

**Date**

*21 October 2015*

Liability limited by a scheme approved under professional standards legislation.

**Children's Leukaemia & Cancer Research Foundation (Inc)****OPERATING STATEMENT**

**For the period 01/07/14 - 30/06/15**

| <b>REVENUE</b>  | <b>2014/2015</b>    | <b>2013/2014</b>    |
|---|---------------------|---------------------|
| <b>Subscriptions</b>                                  | 7,212               | 1,983               |
| <b>Donations &amp; Promotions</b>                     | 150,274             | 128,847             |
| <b>Community Activities</b>                           | 292,394             | 259,278             |
| <b>Raffles &amp; Direct Mail Campaigns</b>            | 518,731             | 649,674             |
| <b>Schools &amp; Associations</b>                     | 12,789              | 7,706               |
| <b>Commercial Support:</b>                            |                     |                     |
| Triple Vend/Austway                                   | 3,099               | 5,125               |
| United Fundraisers                                    | 1,361               | 1,867               |
| VLT   | 1,691               | 1,654               |
| <b>Grants &amp; Bequests:</b>                         |                     |                     |
| Bequests  | 16,127              | 1,555,940           |
| 3BL (Brain Tumour Research Project)                   | 9,671               | 2,478               |
| <b>Interest Received</b>                              | <u>231,018</u>      | <u>229,832</u>      |
| <b>TOTAL REVENUE</b>                                  | <b>\$ 1,244,366</b> | <b>\$ 2,844,383</b> |
| <b>EXPENDITURE:</b>                                   |                     |                     |
| <b>Admin/Salaries &amp; Other Costs</b>               | 561,132             | 317,886             |
| <b>Raffles &amp; Direct Mail Campaigns</b>            | 279,892             | 351,398             |
| <b>Promotions &amp; Events</b>                        | 169,947             | 120,982             |
| <b>Block Grant Funding/Grants:</b>                    |                     |                     |
| Block Grant Allocation                                | 423,792             | 430,151             |
| 1Mio Grant of Excellence                              | 121,517             | 220,598             |
| CLCRF Fellowship                                      | 178,112             | 159,154             |
| Woolworths Fellowship                                 | 108,940             | 112,128             |
| Midline Carcinoma Grant                               | 102,020             | 29,580              |
| Morpholino Therapy for Cancer Grant                   | 67,544              | 49,357              |
| <b>Property Outgoings/Refurbishment</b>               | 38,740              | 29,189              |
| <b>TOTAL EXPENDITURE</b>                              | <b>\$ 2,051,636</b> | <b>\$ 1,820,423</b> |
| <b>EXCESS/(DEFICIT) TRANSFER TO ACCUMULATED FUNDS</b> | <b>\$ (807,269)</b> | <b>\$ 1,023,960</b> |

The accompanying notes form part of the financial statements.



## Children's Leukaemia &amp; Cancer Research Foundation (Inc)

## Balance Sheet - 30/06/2015

|   | Note | 2014/2015           | 2013/2014        |
|---|------|---------------------|------------------|
| <b>ACCUMULATED FUNDS</b>                  |      |                     |                  |
| Balance as at 01/07/2014                  | \$   | 8,246,260           | 7,222,300        |
| Excess/(Deficit) from Operating Statement | \$   | (807,269)           | 1,023,960        |
| <b>TOTAL ACCUMULATED FUNDS</b>            |      | <u>\$ 7,438,990</u> | <u>8,246,260</u> |
| These Funds are represented by:           |      |                     |                  |
| <b>CURRENT ASSETS:</b>                    |      |                     |                  |
| Cash on Hand                              | \$   | 100                 | 100              |
| Cash At Bank                              | \$   | 1,401,057           | 130,911          |
| Gaming Commission                         | \$   | 46,254              | 60,093           |
| Term Deposits                             | \$   | 4,142,106           | 6,050,754        |
| <b>Total Cash Available</b>               | \$   | 5,589,517           | 6,241,858        |
| Trade Debtors                             | \$   | 4,000               | 76               |
| Shares - At Cost                          | \$   | 17,166              | 17,166           |
| Share Options - At Cost                   | \$   | 1                   | 1                |
| Provision for Diminution in Value         | \$   | (12,366)            | (15,566)         |
| <b>Total Current Assets</b>               | \$   | 5,598,318           | 6,243,535        |
| <b>NON-CURRENT ASSETS:</b>                |      |                     |                  |
| <b>Property - Land &amp; Buildings</b>    |      |                     |                  |
| 100 Hay St Subiaco                        | 2 \$ | 886,630             | 886,630          |
| Capital Improvements - Subiaco            | \$   | 121,626             | 121,626          |
| Provision for Diminution in Value         | \$   | (198,256)           |                  |
| Computer Equipment At Cost                | \$   | 7,183               | 7,183            |
| <b>Property - Vacant Land</b>             |      |                     |                  |
| 26 Parnell Pde Bassendean                 | 2 \$ | 572,928             | 572,928          |
| 28 Parnell Pde Bassendean                 | 2 \$ | 553,588             | 553,588          |
| <b>Total Non-Current Assets</b>           | \$   | 1,943,700           | 2,141,955        |
| <b>TOTAL ASSETS</b>                       | \$   | 7,542,017           | 8,385,490        |
| <b>CURRENT LIABILITIES:</b>               |      |                     |                  |
| Trade Creditors                           | \$   | (2,873)             | (2,026)          |
| Accrued/Sundry Creditors                  | \$   | (73,114)            | (115,633)        |
| Leave Liabilities                         | \$   | (65,380)            | (65,274)         |
| Provision for AL/LSL on-costs             | \$   | (6,800)             | (6,800)          |
| Total Years Tax Liabilities               | \$   | 45,139              | 50,500           |
| <b>TOTAL LIABILITIES</b>                  | \$   | (103,028)           | (139,233)        |
| <b>TOTAL ASSETS/(LIABILITIES)</b>         | \$   | <u>7,438,990</u>    | <u>8,246,260</u> |

The accompanying notes form part of the financial statements.

CHILDREN'S LEUKAEMIA & CANCER RESEARCH  
FOUNDATION (Inc)

## NOTE 1 - Statement of Significant Accounting Policies

The significant accounting policies which have been adopted in the preparation of this financial report are:

## BASIS OF PREPARATION

The Financial Report is a special purpose financial report, which has been prepared to meet the requirements of the Management Committee to provide information to the Children's Leukaemia & Cancer Research Foundation (Inc). The Foundation is not a reporting entity and is not obliged to adhere to the mandatory reporting requirements of the Australian Accounting Standards. Notwithstanding the special reporting status of the foundation, the Management Committee have, unless otherwise stated followed generally accepted accounting principles in accordance with Australian Accounting Standards. The accounts have been prepared on the basis of historical costs and do not take into account the changing value or fair value of non-current assets. The Accounting policies are consistent with those prepared in 2014.

## TAXATION AND GST

Children's Leukaemia & Cancer Research Foundation (Inc) is an income tax exempt body.

The Net amount of Goods and Services Tax and GST recoverable from or payable to the Australian Taxation Office is included as a current asset or liability in the Balance Sheet.

Revenue, Expenses and Assets are recognised net of GST.

## EMPLOYEE ENTITLEMENTS

The amounts expected to be paid to employees for their pro-rata entitlement to long service leave and annual leave are accrued annually at current pay rates.

## NOTE 2 - Valuation of Non-Current Assets - Property

Hay Street, Subiaco was purchased on 02/09/2010 and is valued at market valuation. The Market Valuation is at 19/06/15 and is prepared by an independent licensed property valuer. 26 and 28 Parnell Parade, Bassendean, were transferred to the Foundation on 17/09/2013 by a deceased estate. They are valued at Committee of Management valuation based upon a real estate agents Appraisal and Report dated 18/09/2012 and a second real estate agents drive-by valuation dated 08/11/2013.





## CONTACT US

**Children's Leukaemia & Cancer  
Research Foundation (Inc.)**

**Phone:** +61 8 9363 7400

**Fax:** +61 8 9382 9798

**Email:** [admin@childcancerresearch.com.au](mailto:admin@childcancerresearch.com.au)

[www.childcancerresearch.com.au](http://www.childcancerresearch.com.au)